uniQure N.V. (QURE) Debt Components
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $49.94M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $49.70M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $71.92M; Long-Term Debt, Maturity, Year OneUSD $4.79M; Long-Term Debt, Maturity, Year TwoUSD $5.42M.
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $51.88M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
uniQure N.V. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Current Maturities USD | Borrowings under Guaranteed Investment Agreements EUR | Borrowings under Guaranteed Investment Agreements USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Current Borrowing Capacity USD | Line of Credit Facility, Remaining Borrowing Capacity USD | Debt Instrument, Interest Rate, Stated Percentage pure |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $49.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $49.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $71.92M | $4.79M | $5.42M | $10.24M | $26.53M | $24.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $51.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $51.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $51.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $51.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $66.02M | $8.62M | $6.18M | $51.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $51.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $102.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $102.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $101.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $147.57M | $13.42M | $18.23M | $13.38M | $102.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $101.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $101.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $103.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $102.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $144.49M | $14.87M | $12.40M | $117.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $102.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $101.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $101.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $100.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $135.59M | $7.98M | $10.58M | $15.47M | $101.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $71.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $70.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $70.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $35.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $42.41M | $3.14M | $25.00M | $14.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $35.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $35.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $36.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $36.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $46.53M | $4.12M | $3.14M | $25.00M | $14.27M | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2019-09-30 | $35.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2019-06-30 | $35.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2019-03-31 | $35.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2018-12-31 | $35.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $48.18M | $3.12M | $4.12M | $15.66M | $15.66M | $9.62M | (m) | (m) | (m) | $50.00M | $15.00M | $15.00M | 8.85% |
| 2018-12-06 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | (m) |
| 2018-09-30 | $9.60M | (m) | (m) | (m) | (m) | (m) | (m) | $11.11M | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2018-06-30 | $12.84M | (m) | (m) | (m) | (m) | (m) | (m) | $8.03M | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2018-03-31 | $16.37M | (m) | (m) | (m) | (m) | (m) | (m) | $4.44M | (m) | (m) | $50.00M | (m) | (m) | (m) |
| 2017-12-31 | $19.74M | (m) | (m) | (m) | (m) | (m) | (m) | $1.05M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $23.96M | $2.89M | $14.19M | $6.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $14.35M | (m) | (m) | (m) | (m) | (m) | (m) | $6.23M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $16.15M | (m) | (m) | (m) | (m) | (m) | (m) | $4.32M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $17.92M | (m) | (m) | (m) | (m) | (m) | (m) | $2.44M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $19.63M | (m) | (m) | (m) | (m) | (m) | (m) | $605.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.40M | $6.80M | (m) | (m) | (m) | 5.70% |
| 2016-05-06 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.25% |
| 2015-12-31 | $14.63M | (m) | (m) | (m) | (m) | (m) | (m) | $5.58M | 6.10M | $6.60M | (m) | (m) | (m) | 5.70% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |